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Abstract
Objectives-To investigate urine neopterin as a parameter of disease activity in an unselected group of patients with systemic lupus erythematosus (SLE) and to study the relation between urine neopterin and certain patterns of organ disease and differing drug regimens in the treatment of SLE. Methods-Neopterin was determined by high performance liquid chromatography in 115 early morning urine samples from 68 patients with SLE. Serum soluble interleukin 2 receptor (sIL-2R) and antibodies to double stranded DNA (dsDNA) were determined by enzyme linked immunosorbent assay (ELISA), and the erythrocyte sedimentation rate (ESR), plasma C3, C4, and C3 degradation products (C3dg) were measured in corresponding blood samples. Disease activity was scored using the British Isles Lupus Assessment Group (BILAG) index. Results-Urine neopterin was significantly increased in patients with active and inactive SLE compared with the control group and was significantly higher in patients with active than in those with inactive SLE. Urine neopterin did not distinguish between subsets of patients with SLE with particular patterns oforgan disease, as defined by the BILAG index, nor was its level primarily influenced by differing drug regimens. Levels of serum sIL-2R, antibodies to dsDNA, the ESR, and plasma C3, C4, and C3dg were also significantly different between the patients with active and inactive SLE. Unlike urine neopterin there was considerable overlap in the values of these parameters between the two activity groups. Highly significant correlations found between urine neopterin and serum sIL-2R, ESR, and plasma C3, C4, and C3dg suggest the close association of neopterin with clinical activity in SLE. Multivariate logistic regression analysis showed that urine neopterin >300 ,umol/ mol creatinine was a highly significant predictor of disease activity with an odds ratio of 3-51.
Conclusions-Determination of urine neopterin, a non-invasive, relatively simple and inexpensive measurement, appears to be the best parameter for assessing and monitoring disease activity and treatment in patients with SLE. Numerous and varied abnormalities of the immune system have been reported in patients with systemic lupus erythematosus (SLE).1 In particular, increases in circulating T lymphocytes bearing the activation markers HLA-DR and HLA-DP antigens,2 3the early activation antigen TLi-SA14 and membrane bound interleukin 2 receptors (IL-2R)5 have been documented, supporting the concept ofT lymphocyte upregulation. Particular attention has been focused on neopterin as an indicator of activation of the cellular immune system. 6 Neopterin is a pyrazino-pyrimidine derivative formed from guanosine triphosphate within the biosynthetic pathway of biopterin,7 but unlike biopterin, which is an important cofactor in a number of enzymatic reactions, the physiological role of neopterin remains obscure. In vitro experiments have shown that neopterin is specifically produced by human macrophages when stimulated by interferon -y released from activated T lymphocytes. 8 Creatinine was determined separately using a kinetic alkaline picrate (Jaffe) method and neopterin excretion was expressed as pLmolImol creatinine. Serum sIL-2R was measured using a commercially available sandwich enzyme linked immunosorbent assay kit (Cellfree, T Cell Diagnostics, Cambridge, MA, USA). Results were expressed in U/ml relative to a set of standards supplied with the kit.
Other laboratory determinants were performed by standard methods: haemoglobin and white blood cell count with absolute differential count using a Sysmex NE8000 instrument; ESR by the Seditainer ESR system; serum urea and electrolytes on an Ektachem 700XR instrument (Kodak Diagnostic Ltd); plasma C3 and C4 by nephelometry; plasma C3 degradation products (C3dg) by a double decker immunodiffusion method; and antibodies to dsDNA using an ELISA kit from Diamedic Corporation.
STATISTICAL PROCEDURE
Appropriate use of Student's t test and ANOVA enabled comparisons of age, disease duration, and number of ARA criteria fulfilled between groups. For non-parametric study variables, Spearman rank correlation coefficients were computed for pairs of continuous data and the Mann Whitney U test was used to compare continuous variables between two subgroups. When there were more than two subgroups the Kruskall Wallis H test was used. To avoid statistical bias, only data from the initial assessment of patients who had more than one assessment during the study period were included in the correlation analysis.
Forward stepwise logistic regression analysis was chosen to identify the best predictor of SLE disease activity. The predictive variables (represented in binary format) were ESR, C3, C4, C3dg, antibodies to dsDNA dichotomised at 100 and 300 IU/ml, serum sIL-2R dichotomised at 700, 750, 800, and 850 U/ml, and urine neopterin dichotomised at 200 (p<0-000 1) .
The SLE group was found to have a significantly higher median serum sIL-2R (723 U/ml, range 110-2332) than the control group (340 U/ml, range 220-980) with p<0-0001.
Serum sIL-2R levels for the active and inactive SLE groups, with medians of 740 U/ml (range 207-2309) and 720 U/ml (range 110-2332) respectively, were significantly higher than controls (p<0-0001) but the difference in serum sIL-2R levels between the active and inactive SLE groups only reached p<0-05. Figure 2 shows the distribution for ESR, antibodies to dsDNA and plasma C3, C4, and C3dg in the active and inactive SLE groups. Plasma C3 and C4 were significantly lower and ESR and plasma C3dg were significantly higher in the active group. Antibodies to dsDNA were significantly raised in the active group even though 32 of the inactive and 10 of the active samples had values <100 IU/ml, defined in the test as a negative result.
A highly significant correlation was found between urine neopterin and serum sIL-2R with r=0-51, p<0-0001 (fig 3) . Correlations were also found with ESR (r=0-46, p=0-0001), C3 (r=-0-29, p=0-016), C4 (r=-0-32, p=0-0076) and C3dg (r=0-34, p=0-0045). No significant correlation with antibodies to dsDNA was detected.
Only two study parameters, urine neopterin >300 pLmol/mol creatinine and plasma C4 <0-11 g/l, were significant predictors of SLE disease activity using multivariate logistic regression analysis. Urine neopterin >300
iimol/mol creatinine was the most significant of the two with an odds ratio of 3-51 (95% confidence interval 1-55 to 7-93, p=0 003). The odds ratio for plasma C4 <0 11 g/l was 414 (95% confidence interval 1-53 to 11-23, p=0 005). Table 2 gives the sensitivity, specificity, and positive and negative predictive values of levels of urine neopterin in identifying disease activity.
When urine neopterin values were compared for active SLE patients receiving different forms of treatment (fig 4) , significant differences were found among the four subgroups using the Kruskall-Wallis H test (p=0024).
The subgroup receiving prednisolone and cytotoxic drugs had significantly lower urine neopterin values that the subgroups receiving prednisolone only (p=0O003) and cytotoxic drugs only (p<O0OOOl). A similar analysis for serum sIL-2R, ESR, antibodies to dsDNA, and plasma C3, C4, and C3dg showed that the subgroups receiving prednisolone and cytotoxic drugs as well as those receiving cytotoxic drugs only had significantly higher plasma C3 levels than prednisolone subgroup (p<00001). No significant differences were found for other subgroup comparisons for each of these parameters.
Urine neopterin values for patients with activity in multiple organ systems (median 389, range 108-783) were significantly higher than Serum slL-2R (U/ml) Figure 3 Correlation between serum soluble int receptor (sIL-2R) and urine neoptenin in 68 pat systemtc lupus erythematosus. certain previous studies.29 30 The highly significant correlation between urine neopterin and serum sIL-2R, ESR, and creatinine and plasma C4 <0 11 g/l were found to be significant predictors of SLE disease activity on multivariate logistic regression analysis compared with the other study parameters. Urine neopterin at this level was further shown to have the best positive predictive value (67%) with a sensitivity and specificity of 62 and 72% respectively. In contrast, plasma C4<0-11 g/l showed less discriminatory power due to a greater overlap between the patients with active and inactive SLE. These calculations are based on the assumption that the BIIAG index is 100% sensitive and 100% specific in defining SLE activity, but there remains no general agreement on the most valuable SLE disease activity index. Why the subgroup receiving prednisolone and cytotoxic drugs had significantly lower urine neopterin values than those receiving prednisolone or cytotoxic drugs only is not obvious. Treatment with drugs, for example, steroids, affects the proportion of lymphocyte subpopulations and the expression of cell surface molecules and hence could potentially influence neopterin production.2 Drugs do affect clinical disease activity and it is difficult to investigate a possible additional direct effect of drugs on neopterin levels. Analyses of the other study parameters suggest that the patients receiving prednisolone only generally had more active disease than the other subgroups, but differences did not reach statistical significance apart from plasma C3 concentrations. Urine neopterin therefore appears to be a reflection of treatment efficacy in suppressing disease activity rather than a direct drug related effect, and this agrees with the findings in other inflammatory diseases.3 ' 32 In view of the small numbers in this part of the study, however, a type I error cannot be excluded and further studies are required to clarify this issue.
No significant differences between urine neopterin in patients with different patterns of organ system disease were observed, suggesting that increased urine neopterin excretion and hence the activation of the cellular immune system occurs regardless of the major organ affected in SLE. The significantly higher urine neopterin values in the group with multiple organ system disease agree with these patients having generally more active disease. This is in contrast to changes in levels of antibodies to dsDNA and complement which have been reported to accompany flares in lupus nephritis. 30 33 Sensitive and accurate radioimmunoassays and high performance liquid chromatographic methods have been developed for the measurement of neopterin in body fluids.'5 34 We chose to measure neopterin in urine by high performance liquid chromatography as this method has good performance characteristics, is easily automated and is non-invasive. In contrast, serum neopterin levels are dependent on renal function35 and the determination of urine neopterin by radioimmunoassay can give erroneous results related to the poor specificity of the antisera.34
In conclusion, urine neopterin appears to be the best single parameter of disease activity in patients with SLE. It is a non-invasive, relatively simple and inexpensive test which seems to be clinically useful for assessing and monitoring disease activity and treatment in patients with SLE. It must be noted, however, that it is not specific to SLE nor can it distinguish between disease exacerbations and infective episodes.36 Neopterin may prove to be an early indicator of disease flares in patients with SLE but this would require long term serial studies.
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